Table 3.
Anti-SARS-CoV-2 IgG levels based on vaccines, doses and COVID-19 infection history.
| Groups | Number (%) | Median (IQR) Anti-SARS-CoV-2 IgG levels (BAU) | p | Seronegativity rate,% (n) | Rate of participants with a maximum titer,% (n) |
|---|---|---|---|---|---|
| 2IV(-) | 54 (16.8%) | 88.27 (25.64–247.17) |
p < 0.001 | 20.37% (n = 11) | 7.4%, (n = 4) |
| 2IV(+) | 29 (9.0%) | 626.54 (238.68–4782.92) |
0% | 10.34%, (n = 3) | |
| 3IV(-) | 13 (4.0%) | 1361.11 (441.36–5128.09) |
p > 0.05 | 0% | 0% |
| 3IV(+) | 10 (3.1%) | 1409.47 (969.39–4060.70) |
0% | 10%, (n = 1) | |
| 2IV/mRNA(-) | 162 (50.3%) | 12,860 (9437.76–12,860) |
p > 0.05 | 0% | 53.9%, (n = 86) |
| 2IV/mRNA(+) | 54 (16.8%) | 11,871.91 (5912.55–12,860) |
0% | 46.3%, (n = 25) |